Your browser doesn't support javascript.
loading
Optimizing the Region for Evaluation of Global Gamma Analysis for Nasopharyngeal Cancer (NPC) Pretreatment IMRT QA by COMPASS: A Retrospective Study.
Lu, Wenli; Li, Ying; Huang, Wei; Cui, Haixia; Zhang, Hanyin; Yi, Xin.
Afiliação
  • Lu W; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Li Y; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Huang W; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Cui H; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Zhang H; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Yi X; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Oncol ; 12: 859415, 2022.
Article em En | MEDLINE | ID: mdl-35774127
ABSTRACT

Background:

The global gamma passing rate is the most commonly used metric for patient-specific pretreatment quality assurance in radiation therapy. However, the optimal region for evaluation and specific action limits (ALs) need to be explored. Therefore, this study was carried out to explore the optimal region for evaluation of the global gamma passing rate and define ALs by using the COMPASS software.

Methods:

A total of 93 intensity-modulated radiation therapy (IMRT) plans for nasopharyngeal cancer (NPC) patients, including 61 original plans and 32 multileaf collimator (MLC) error-introduced test plans, were selected for retrospective analysis. Firstly, the dose distribution was divided into six isodose regions ("≥10%", "≥20%", "≥30%", "≥40%", "≥50%", and "≥60%") based on the prescribed dose and one clinically oriented region for evaluation ("whole") to perform the three-dimensional (3D) global gamma reanalysis. Meanwhile, the percentage gamma passing rate (%GP), mean gamma index (µGI) based on 3%/2 mm criteria, and percentage dose error (%DE) of the dose-volume histogram (DVH) metrics were recorded by COMPASS application. Secondly, the Pearson's correlation coefficient was used to analyze the correlation between %GP and %DE and between µGI and %DE in different regions. Additionally, receiver operating characteristic (ROC) methodology was applied to quantify the fraction of patient-specific plans evaluated as "fail" and "pass". In order to improve the correlation between gamma analysis result and clinical criteria, ROC analysis was carried out in accordance with hybridization analysis criteria (%DE ≤3%, %GP ≥90% and %DE ≤3%, µGI ≤0.6). ROC was performed for two

purposes:

1) to analyze the sensitivity and specificity of %GP and µGI in different regions for evaluation and 2) to define the ALs of %GP and µGI in the optimal region for evaluation. Finally, the plans introduced with MLC errors were prepared for validation. Moreover, we also compared the positive rate of ALs of both %GP and µGI in detecting MLC error-introduced plans in different regions.

Results:

1) In our study, a number of DVH-based metrics were found to be correlated with the evaluation parameters. The corresponding number was 4, 2, 1, 1, 1, 1, and 3 in γwhole, γ10%, γ20%, γ30%, γ40%, γ50%, and γ60%, respectively, and 5, 3, 0, 1, 1, 4, and 2 in µGIwhole, µGI10%, µGI20%, µGI30%, µGI40%, µGI50%, and µGI60%, respectively. The results by COMPASS have revealed that the %DE of specific structures has a slightly higher correlation with both %GP and µGI of the "whole" region compared with that of any other region. However, it is a moderate correlation (0.5 ≤ |r| < 0.8). 2) The areas under the curves (AUCs) of γwhole, µGIwhole, µGI40%, µGI50%, and µGI60% were >0.7 based on 3%/2 mm criteria. According to the Youden coefficient, we defined the ALs of γwhole ≥92%, µGIwhole ≤0.36, µGI40% ≤0.43, and µGI60% ≤0.40 based on 3%/2 mm criteria. 3) In the validation, for original plans, the accuracy of ALγwhole, ALγ10%, ALµGIwhole, ALµGI40%, ALµGI50%, and ALµGI60% was 23%, 9.8%, 90%, 80.3%, 9.8%, and 88.5%, respectively. For test plans with systematic MLC errors smaller than 0.8 mm, the positive rates of ALγwhole, ALγ10%, ALµGIwhole, ALµGI40%, ALµGI50%, and ALµGI60% were 25%, 58%, 92%, 92%, 42%, and 100%, respectively. For the plans with systematic MLC errors higher than 0.8 mm, the positive rates of all AL%GP and ALµGI were 100%. From the COMPASS validation results, the accuracy of γwhole, µGIwhole, µGI40%, and µGI60% was higher than that of the conventional γ10% and commonly used µGI50%.

Conclusions:

Compared with the traditional evaluation region (i.e., the criteria with a threshold of 10% or a threshold of 50%, it was the same with the isodose regions of "≥10%", "≥50%" based on the prescribed dose in our study), the "whole" region is more meaningful to the clinic by COMPASS. The accuracy of µGIwhole is higher than that of the conventional γ10% and the commonly used µGI50%.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
...